BILYPSA TAB

Description

Bilypsa Tablet is a novel prescription medication primarily used to treat non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and dyslipidemia. It contains Saroglitazar, a dual PPAR α/γ agonist that works by reducing elevated triglycerides and improving insulin sensitivity, thereby managing lipid metabolism and liver health.

Bilypsa is particularly effective in patients with metabolic syndrome, type 2 diabetes, and obesity-related liver disorders. By targeting both lipid and glucose pathways, it not only improves liver enzyme levels but also helps prevent the progression of fatty liver to cirrhosis or liver fibrosis.

The tablet is generally well-tolerated and prescribed under medical supervision. Regular liver function monitoring and lipid profiling are recommended during therapy.

Key Benefits:

• Treats NAFLD and NASH

• Lowers elevated triglyceride and cholesterol levels

• Improves liver enzyme function

• Reduces insulin resistance

• Beneficial for patients with diabetes and metabolic syndrome